Tag Archives: orphan drug

Orphan Drug Investors Discuss the Current Rare Disease Environment during RESI@JPM

21 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

A large number of early stage biotechs are pursuing orphan disease indications.  This trend is driven by the large number of rare diseases with either no current treatment options or severely inadequate therapies as well as the unique regulatory/development advantages available for these therapeutics. However, orphan drugs also face some unique challenges, such as clinical trial recruitment, pricing, and small market sizes. Recent developments in the space should make for an interesting year to come with the new FDA head, Dr. Scott Gottlieb, planning to eliminate the backlog of orphan drug designation requests and the halving of the orphan drug tax credit.

In the highly anticipated RESI @ JPM conference on January 9, 2018, a varied group of investors active in the orphan/rare disease space will discuss the financing and business development environment for startups working on developing drugs for orphan indications.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital panelists include:

Orphan Drug Investors Share Their Insights at RESI San Diego

11 May

By Lucy Parkinson, Director of Research, LSN

Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.

At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:

%d bloggers like this: